The Quantellect read.As of Nov 19, 2026, 7 active firms cover BioCryst Pharmaceuticals Inc: 5 rate it Buy or better, 2 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $11.00 to $32.00 (about 2.9x), a sign of real disagreement on valuation. The average target of $21.29 sits 192% above the current $7.29. The rating mix has stayed broadly stable, with Buy-side ratings easing from 8 to 5 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.17 next quarter toward $0.85 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 active firms
Buy
Strong Buy00%
Buy571%
Neutral229%
Sell00%
Strong Sell00%
Based on 7 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$21.29
+191.8% upside
Average target across 7 active firms as of Nov 19, 2026 vs $7.30 current
Highest Target$32.00
Average Target$21.29
Lowest Target$11.00
Detailed analyst forecasts for BCRX
Showing 1–7 of 7 named analysts shown · 7 active firms in the rating projection
As of Nov 19, 2026, 5 of 7 active firms rate BCRX a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
BCRX EPS & revenue forecast
EPS · NEXT QUARTER
$0.17
Range $0.17 – $0.18 · 2 analysts · +25% YoY
Next period, 2 analysts expect BioCryst Pharmaceuticals Inc to earn $0.17 a share (range $0.17 – $0.18), versus $0.14 a year earlier. Full-year consensus is $0.86, growing to $0.85 the year after.
REVENUE · NEXT QUARTER
$166.9M
Range $160.0M – $172.2M · 2 analysts · +7% YoY
Revenue is expected to reach $166.9M (range $160.0M – $172.2M), +6.7% year-over-year. Full-year consensus is $718.4M, rising to $736.1M next year.
Top analysts covering BioCryst Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BCRX.
#1
Jonathan Wolleben
JMP Securities · Rank #54
Buy
$28.00+283.8% to target
Overall win rate
43%
+ Follow
#2
Laura Chico
Wedbush · Rank #55
Buy
$20.00+174.2% to target
Overall win rate
46%
+ Follow
#3
Andrew Fein
HC Wainwright & Co. · Rank #73
Buy
$32.00+338.7% to target
Overall win rate
45%
+ Follow
#4
Jessica Fye
JP Morgan · Rank #100
Neutral
$13.00+78.2% to target
Overall win rate
54%
+ Follow
#5
Serge Belanger
Needham · Rank #129
Buy
$16.00+119.3% to target
Overall win rate
46%
+ Follow
BCRX stock forecast FAQ
What is BCRX's average 12-month price target?+
The 7 active firms with a live target average $21.29 for BioCryst Pharmaceuticals Inc over the next 12 months, ranging from a $32.00 high to a $11.00 low, as of Nov 19, 2026.
Is BCRX stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 7 active firms as of Nov 19, 2026, 5 rate it Buy or Strong Buy, 2 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for BCRX?+
The Street-high target is $32.00 (HC Wainwright & Co.), and the Street-low is $11.00 (RBC Capital). The average of all 7 active-firm targets is $21.29.
How many active Wall Street firms cover BCRX?+
7 active firms have a recognized rating on BioCryst Pharmaceuticals Inc as of Nov 19, 2026, and 7 active firms carry a live 12-month price target.
Who is the most accurate analyst covering BCRX?+
Among analysts who currently cover BCRX, Jonathan Wolleben of JMP Securities has the strongest overall Quantellect track record (Rank #54). Their current call is Buy with a $28.00 target.
What is BioCryst Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $0.17 per share (range $0.17 – $0.18) across 2 analysts. Full-year EPS is projected at $0.86, rising to $0.85 the following year.
How much revenue is BioCryst Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $166.9M (range $160.0M – $172.2M). Full-year revenue is projected at $718.4M, growing to $736.1M next year.
Have analysts been upgrading or downgrading BCRX lately?+
As of Nov 19, 2026, 5 of 7 active firms rate BCRX a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BCRX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.